Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2008-12-30
Anderson, Rebecca L (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S277000
Reexamination Certificate
active
07470696
ABSTRACT:
The present invention provides compounds of formula Iand pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase enzymes thereby making them useful as anti-cancer agents.
REFERENCES:
patent: 6465484 (2002-10-01), Bilodeau et al.
patent: 2002/0103230 (2002-08-01), Renhowe et al.
patent: 3722992 (1989-01-01), None
patent: 1300396 (2003-04-01), None
patent: 63-230687 (1988-09-01), None
patent: WO 01/96308 (2001-12-01), None
patent: WO 02/079192 (2002-10-01), None
patent: WO 03047577 (2003-06-01), None
Wassmann et al., Circulation, 2002, 105, pp. 2083-2091.
Cancer and Metastasis Reviews (1998), 17(1), 91-106.
Science (1999), vol. 286, 531-537.
U.S. Appl. No. 10/263,448, filed Oct. 2, 2002, Wittman et al.
U.S. Appl. No. 10/674,098, filed Sep. 29, 2003, Velaparthi et al.
Beaulieu Francis
Ouellet Carl
Velaparthi Upender
Wittman Mark D.
Zimmermann Kurt
Anderson Rebecca L
Bristol--Myers Squibb Company
Korsen Elliott
Liu Hong
LandOfFree
Tyrosine kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tyrosine kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine kinase inhibitors will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4043326